Targeted Therapies Have Most Clinically Useful Biomarker Labeling
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pharmacogenetic biomarkers for molecularly targeted therapies are supported by considerably better evidence that they improve patient outcomes than biomarkers in labeling of untargeted drugs, but a JAMA study still found that half of biomarkers in label lacked convincing evidence of clinical utility.
You may also be interested in...
Biomarkers In Labeling Lack Clinical Utility Evidence
FDA-approved labels for more than 100 drugs feature pharmacogenomic biomarker data, but only one-sixth of those biomarkers are supported by data showing a clear association with health benefits, a JAMA study found. Researchers recommend stricter standards and a standardized pharmacogenomics section of labeling.
Autoimmune Drug Reactions To Get Further FDA Research After Ziagen Side Effect Findings
Carriers of the HLAB*57:01 allele who take Ziagen can come down with severe autoimmune reactions due to a mechanism traced by agency researchers.
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.